Fig. 1: Serological profile of the Cord Blood Samples collected between October 2021 and February 2023. | Nature Communications

Fig. 1: Serological profile of the Cord Blood Samples collected between October 2021 and February 2023.

From: Cord blood IgA/M reveals in utero response to SARS-CoV-2 with fluctuations in relation to circulating variants

Fig. 1

a Evaluation of SARS-CoV-2 specific IgG in 1405 Cord Blood Samples (CBS). All CBS were tested for SARS-CoV-2 specific anti-RBD (Receptor Binding Domain) and anti-N (Nucleocapsid) IgG antibodies. Samples with anti-RBD above positivity threshold are represented in color: Samples with anti-RBD ⩾700 MFI (Median Fluorescence Intensity) and anti-N < 300 MFI (bright yellow), anti-RBD ⩾700 MFI and anti-N = 300–699 MFI (orange) and anti-RBD ⩾700 MFI and anti-N ⩾700 MFI (red). Source Data are provided as a Source Data File. b Anti-SARS-CoV-2 IgG in 1405 cord blood samples (CBS) collected between October 2021 and February 2023. Biweekly count of anti-RBD (Receptor Binding Domain) and anti-N (Nucleocapsid) antibodies represented in color: CBS with anti-RBD < 700 MFI (Median Fluorescence Intensity) (light yellow), anti-RBD ⩾700 MFI and anti-N < 300 MFI (bright yellow), anti-RBD ⩾700 MFI and anti-N between 300–699 MFI (orange), and samples with anti-RBD ⩾700 MFI and anti-N ⩾700 MFI (red). Source Data are provided as a Source Data File. c Detectable SARS-CoV-2 IgA and/or IgM in 1038 cord blood samples (CBS) with IgG anti-N (Nucleocapsid) ⩾300 MFI. Biweekly count of samples positive for anti-SARS-CoV-2 IgA or IgM (dark blue) versus negative for both (light blue). Source Data are provided as a Source Data File.

Back to article page